Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2017 | Managing side effects in treatment of bladder cancer

Morgan Roupret • 25 Mar 2017
EAU 2017
Genitourinary Cancer

Morgan Roupret, MD, PhD, from the Pitié-Salpétrière Hospital, Paris, France, discusses management of side effects in treatment of bladder cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He states that in the near future, medication delivered directly to the bladder will be available to reduce the side effects of BCG and chemotherapy.

More from Morgan Roupret

Surgical outcomes of neoadjuvant durvalumab and chemotherapy in UTUC
1:16
Surgical outcomes of neoadjuvant durvalumab and chemotherapy in UTUC
Morgan Roupret • 14 Feb 2025
Why does the EAU stand out from other oncology conferences?
1:25
Why does the EAU stand out from other oncology conferences?
Morgan Roupret • 25 Mar 2017
Preventing cystectomy in patients with advanced or complicated bladder cancer
0:54
Preventing cystectomy in patients with advanced or complicated bladder cancer
Morgan Roupret • 25 Mar 2017
How can we optimize contemporary bladder cancer care?
1:34
How can we optimize contemporary bladder cancer care?
Morgan Roupret • 26 Mar 2017

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals